Possible anti-Parkinson properties of N-(α-linolenoyl) tyrosine: A new molecule

Shlomo Yehuda

doi:10.1016/s0091-3057(01)00646-3

Possible anti-Parkinson properties of N-(α-linolenoyl) tyrosine: A new molecule

Shlomo Yehuda

Department of Psychology

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Tyrosine is unable to cross the blood-brain barrier and is therefore unable to improve the status of brain dopamine (DA) and to provide relief for patients with Parkinson's disease (PD) or other DA-insufficient disorders. We report the creation of an amide bond molecule [N-(α-linolenoyl)tyrosine (NLT)] that combines tyrosine with a fatty acid mixture. NLT significantly improves the rotational behavior of rats [following unilateral striatal lesions (as a model for Parkinson's)] and overcomes the exaggerated eye-blinking induced by a potent DA-depleting agent (as a model for essential blepharospasm). These results are supported by the finding that NLT's mode of action, in striatum, is the same as the mode of action of D-amphetamine. They both induce an increase in the DA level, DA turnover and release.

Original language	English
Pages (from-to)	7-11
Number of pages	5
Journal	Pharmacology Biochemistry and Behavior
Volume	72
Issue number	1-2
DOIs	https://doi.org/10.1016/s0091-3057(01)00646-3
State	Published - May 2002

Keywords

Amide bond
Animal model
Dopamine
Parkinson's disease
Tyrosine
α-Linolenic acid

Access to Document

10.1016/s0091-3057(01)00646-3

Cite this

@article{4bfb6e12108846afbcb1759c0e1613bf,

title = "Possible anti-Parkinson properties of N-(α-linolenoyl) tyrosine: A new molecule",

abstract = "Tyrosine is unable to cross the blood-brain barrier and is therefore unable to improve the status of brain dopamine (DA) and to provide relief for patients with Parkinson's disease (PD) or other DA-insufficient disorders. We report the creation of an amide bond molecule [N-(α-linolenoyl)tyrosine (NLT)] that combines tyrosine with a fatty acid mixture. NLT significantly improves the rotational behavior of rats [following unilateral striatal lesions (as a model for Parkinson's)] and overcomes the exaggerated eye-blinking induced by a potent DA-depleting agent (as a model for essential blepharospasm). These results are supported by the finding that NLT's mode of action, in striatum, is the same as the mode of action of D-amphetamine. They both induce an increase in the DA level, DA turnover and release.",

keywords = "Amide bond, Animal model, Dopamine, Parkinson's disease, Tyrosine, α-Linolenic acid",

author = "Shlomo Yehuda",

year = "2002",

month = may,

doi = "10.1016/s0091-3057(01)00646-3",

language = "אנגלית",

volume = "72",

pages = "7--11",

journal = "Pharmacology Biochemistry and Behavior",

issn = "0091-3057",

publisher = "Elsevier Inc.",

number = "1-2",

}

TY - JOUR

T1 - Possible anti-Parkinson properties of N-(α-linolenoyl) tyrosine

T2 - A new molecule

AU - Yehuda, Shlomo

PY - 2002/5

Y1 - 2002/5

N2 - Tyrosine is unable to cross the blood-brain barrier and is therefore unable to improve the status of brain dopamine (DA) and to provide relief for patients with Parkinson's disease (PD) or other DA-insufficient disorders. We report the creation of an amide bond molecule [N-(α-linolenoyl)tyrosine (NLT)] that combines tyrosine with a fatty acid mixture. NLT significantly improves the rotational behavior of rats [following unilateral striatal lesions (as a model for Parkinson's)] and overcomes the exaggerated eye-blinking induced by a potent DA-depleting agent (as a model for essential blepharospasm). These results are supported by the finding that NLT's mode of action, in striatum, is the same as the mode of action of D-amphetamine. They both induce an increase in the DA level, DA turnover and release.

AB - Tyrosine is unable to cross the blood-brain barrier and is therefore unable to improve the status of brain dopamine (DA) and to provide relief for patients with Parkinson's disease (PD) or other DA-insufficient disorders. We report the creation of an amide bond molecule [N-(α-linolenoyl)tyrosine (NLT)] that combines tyrosine with a fatty acid mixture. NLT significantly improves the rotational behavior of rats [following unilateral striatal lesions (as a model for Parkinson's)] and overcomes the exaggerated eye-blinking induced by a potent DA-depleting agent (as a model for essential blepharospasm). These results are supported by the finding that NLT's mode of action, in striatum, is the same as the mode of action of D-amphetamine. They both induce an increase in the DA level, DA turnover and release.

KW - Amide bond

KW - Animal model

KW - Dopamine

KW - Parkinson's disease

KW - Tyrosine

KW - α-Linolenic acid

UR - http://www.scopus.com/inward/record.url?scp=0036210948&partnerID=8YFLogxK

U2 - 10.1016/s0091-3057(01)00646-3

DO - 10.1016/s0091-3057(01)00646-3

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 11900763

AN - SCOPUS:0036210948

SN - 0091-3057

VL - 72

SP - 7

EP - 11

JO - Pharmacology Biochemistry and Behavior

JF - Pharmacology Biochemistry and Behavior

IS - 1-2

ER -

Possible anti-Parkinson properties of N-(α-linolenoyl) tyrosine: A new molecule

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this